https://www.bioworld.com/rss en-us http://www.bioworld.com/articles/730076 Thu, 02 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730076-ambrosia-slurps-up-a-100m-series-b-for-its-oral-obesity-drug-pipeline Pills, bottle, scale and-measuring tape http://www.bioworld.com/articles/730060 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730060-series-b-financing-supports-ambrosias-cardiometabolic-pipeline Blue digital dollar sign http://www.bioworld.com/articles/730034 Fri, 27 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730034-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs Hand holding dollar sign http://www.bioworld.com/articles/729903 Thu, 26 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729903-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs Hand holding dollar sign http://www.bioworld.com/articles/729747 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729747-crossbow-raises-77m-series-b-for-t-cell-mimicking-antibodies Antibodies illustration http://www.bioworld.com/articles/729055 Thu, 26 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729055-genedit-changes-name-closes-series-b-for-new-therapeutic-programs 3D dollar sign http://www.bioworld.com/articles/729231 Tue, 24 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/729231-quantx-raises-85m-to-advance-oral-immunology-drugs Interleukin 17 (IL-17) http://www.bioworld.com/articles/728990 Fri, 13 Feb 2026 09:00:00 -0500 https://www.bioworld.com/articles/728990-quantx-raises-85m-to-advance-oral-immunology-drugs Interleukin 17 (IL-17) http://www.bioworld.com/articles/728848 Thu, 12 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728848-quantx-raises-85m-to-advance-oral-immunology-drugs Interleukin 17 (IL-17) http://www.bioworld.com/articles/728806 Tue, 10 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/728806-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. http://www.bioworld.com/articles/728800 Tue, 10 Feb 2026 09:00:00 -0500 https://www.bioworld.com/articles/728800-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. http://www.bioworld.com/articles/728701 Mon, 09 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728701-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. http://www.bioworld.com/articles/728547 Tue, 03 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728547-switching-off-resistance-lixas-bold-amr-bet Maud Eijkenboom, CEO, Lixa Pty Ltd. Maud Eijkenboom, CEO, Lixa Pty Ltd. http://www.bioworld.com/articles/728517 Tue, 03 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728517-genentech-licenses-sanegenes-rnai-asset-in-17b-deal Interfering RNA (RNAi) http://www.bioworld.com/articles/728132 Tue, 20 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728132-exciva-adds-599m-series-b-for-alzheimers-disease-agitation-trial White Euro symbol on blue background http://www.bioworld.com/articles/727743 Thu, 08 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/727743-series-b-financing-at-mediar-therapeutics Doctor with illustration of kidneys BioWorld. “Nothing to do but reading and thinking.”]]> http://www.bioworld.com/articles/727531 Wed, 31 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/727531-blossomhill-advancing-egfr-clk-inhibitors-with-series-b-extension Blue dollar sign on white background http://www.bioworld.com/articles/727442 Wed, 24 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727442-further-financing-at-vyriad-to-advance-vv-169-into-clinic Dollar sign droplet above test tube BioWorld, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]> http://www.bioworld.com/articles/727277 Wed, 17 Dec 2025 09:00:00 -0500 https://www.bioworld.com/articles/727277-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery Kim Woo-youn, CEO and cofounder, Hits Kim Woo-youn, CEO and cofounder, Hits BioWorld, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]> http://www.bioworld.com/articles/727003 Tue, 16 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/727003-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery Kim Woo-youn, CEO and cofounder, Hits Kim Woo-youn, CEO and cofounder, Hits http://www.bioworld.com/articles/727230 Tue, 16 Dec 2025 00:00:00 -0500 https://www.bioworld.com/articles/727230-d3-bio-raises-108m-series-b-to-move-kras-g12c-into-phase-iii KRAS protein KRAS protein. Credit: National Cancer Institute, NIH http://www.bioworld.com/articles/726892 Wed, 10 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/726892-d3-bio-raises-108m-series-b-to-move-kras-g12c-into-phase-iii KRAS protein KRAS protein. Credit: National Cancer Institute, NIH http://www.bioworld.com/articles/726802 Thu, 04 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/726802-series-b-financing-supports-trianas-molecular-glue-degraders Gold dollar sign inside gold cog http://www.bioworld.com/articles/726604 Mon, 01 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/726604-protego-secures-130m-in-series-b-for-its-al-amyloidosis-program http://www.bioworld.com/articles/725685 Tue, 28 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725685-ena-respiratory-raises-au34m-series-b-to-fund-phase-ii-trial Ena Respiratory's INNA-051 Ena Respiratory's INNA-051 is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of viral respiratory infections and prevent severe complications in at-risk populations. Credit: Ena Respiratory Pty Ltd. http://www.bioworld.com/articles/725389 Thu, 23 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725389-ena-respiratory-raises-au34m-series-b-to-fund-phase-ii-trial Ena Respiratory's INNA-051 Ena Respiratory's INNA-051 is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of viral respiratory infections and prevent severe complications in at-risk populations. Credit: Ena Respiratory Pty Ltd. http://www.bioworld.com/articles/725076 Wed, 15 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725076-pelages-regenerative-approach-to-hair-loss-draws-120m-in-series-b Thinning hairline http://www.bioworld.com/articles/725064 Tue, 14 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725064-series-b-rounds-abound-with-kardigans-254m-kaileras-600m Black dollar sign on ombre blue background http://www.bioworld.com/articles/724748 Fri, 03 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/724748-cartography-biosciences-series-b-financing-will-advance-lead-program Blue dollar sign on white background http://www.bioworld.com/articles/724033 Tue, 09 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/724033-epigenic-raises-60m-series-b-for-gene-therapies DNA, dollars illustration